MedWatch

ALK closes largest deal in 10 years – gets DKK 90m for partnership in China on adrenaline autoinjector

Allergy firm ALK has entered a collaboration with Chinese company Grandpharma, which pays DKK 90m for the right to sell ALK's adrenaline autoinjector Jext in China. ALK further gains earnings from the sales, and ALK CEO Carsten Hellmann predicts this will be visible on both the company's top and bottom line many years from now.

ALK CEO Carsten Hellmann | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

On Friday, Denmark-based allergy company ALK announced it had entered a partnership with Chinese company Grandpharma to distribute and sell ALK's adrenaline pen Jext in the populous country over the next 16 years.

"This is a huge deal. It's the size of the deal we made 10 years ago for Torii, so this is massive for ALK. Absolutely," ALK CEO Carsten Hellmann tells Medwatch with reference to ALK's Japanese partnership.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs